Angiotensin 1‐7 inhibits angiotensin II‐stimulated head and neck cancer progression

Hinsley, Emma E.; Oliveira, Carine Ervolino de; Hunt, Stuart; Coletta, Ricardo D.; Lambert, D

doi:10.1111/eos.12356

Cited by 26 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiotensin-(1–7) is a direct product of ACE2, and through binding with the Mas receptor has been shown to advance angiogenesis in injured cardiac tissue (myocardial infarction), by increasing expression of VEGF-D and MMP-9 [ 87 ], and in stroke [ 88 ]. Other studies have suggested that ACE2, either by reducing angiotensin II or through activities of the ACE2/angiotensin-(1–7)/MasR axis, may be negatively associated with angiogenesis in various cancers [ 81 , 89 – 91 ]. It also appears to play a role in angiogenesis in uterus during pregnancy [ 92 ].…”

Section: Discussionmentioning

confidence: 99%

Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2

Barker

Parkkila

2020

PLoS ONE

View full text Add to dashboard Cite

The World Health Organization declared the COVID-19 epidemic a public health emergency of international concern on March 11th, 2020, and the pandemic is rapidly spreading worldwide. COVID-19 is caused by a novel coronavirus SARS-CoV-2, which enters human target cells via angiotensin converting enzyme 2 (ACE2). We used a number of bioinformatics tools to computationally characterize ACE2 by determining its cell-specific expression in trachea, lung, and small intestine, derive its putative functions, and predict transcriptional regulation. The small intestine expressed higher levels of ACE2 mRNA than any other organ. By immunohistochemistry, duodenum, kidney and testis showed strong signals, whereas the signal was weak in the respiratory tract. Single cell RNA-Seq data from trachea indicated positive signals along the respiratory tract in key protective cell types including club, goblet, proliferating, and ciliary epithelial cells; while in lung the ratio of ACE2 -expressing cells was low in all cell types (<2.6%), but was highest in vascular endothelial and goblet cells. Gene ontology analysis suggested that, besides its classical role in the renin-angiotensin system, ACE2 may be functionally associated with angiogenesis/blood vessel morphogenesis. Using a novel tool for the prediction of transcription factor binding sites we identified several putative binding sites within two tissue-specific promoters of the ACE2 gene as well as a new putative short form of ACE2 . These include several interferon-stimulated response elements sites for STAT1, IRF8, and IRF9. Our results also confirmed that age and gender play no significant role in the regulation of ACE2 mRNA expression in the lung.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2

Barker

Parkkila

2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…One of the such important modulator is the presence of functional renin-angiotensin system (RAS). Angiotensin II (Ang II), a crucial component of RAS has been reported to have protumoral roles in carcinogenesis [2].…”

Section: Biological Behavior Of Oral Squamous Cell Carcinoma In the Bmentioning

confidence: 99%

“…Ang II is reported to play a vital role in carcinogenesis and apart from its systemic actions, it also exerts local effects. It can promote angiogenesis and cellular proliferation [2]. It also mediates the invasion of OSCC cells, thus facilitating its metastasis.…”

Section: Biological Behavior Of Oral Squamous Cell Carcinoma In the Bmentioning

confidence: 99%

See 1 more Smart Citation

Biological behavior of oral squamous cell carcinoma in the background of novel corona virus infection

Sarode

Sengupta

et al. 2020

Oral Oncology

View full text Add to dashboard Cite

“…Studies have reported that angiogenesis is essential for tumor progression and metastasis (10,11). Furthermore, studies have demonstrated that ARBs have the potential possibility to restrain the growth of several types of cancer cells (12,13). Ang II binds two receptor subtypes, the Ang II type 1 receptor (AT1R) and the Ang II type 2 receptor (AT2R), to mediate a series of biological effects (14).…”

Section: Introductionmentioning

confidence: 99%

Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway

Zhang

Wang

2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Expression of angiotensin II (Ang II), a key biological peptide in the renin-angiotensin system, is closely associated with the occurrence and development of cancer. Ang II binds two receptor subtypes, the Ang II type 1 receptor (AT1R) and the AT2R, to mediate a series of biological effects. Telmisartan, a specific AT1R blocker, has been reported to have potential as an anticancer drug for treating renal cancer. In the present study, whether telmisartan had an effect on non-small cell lung cancer (NSCLC) cell proliferation and migration was investigated. The Cell Counting kit-8 assay revealed that telmisartan significantly inhibited the growth of the NSCLC A549 cell line in a time-and dose-dependent manner. In a transwell assay, telmisartan significantly inhibited cellular invasion and migration. Furthermore, it was determined that the expression of the anti-apoptotic protein B-cell lymphoma was decreased, and that of the pro-apoptotic proteins caspase-3 and Bcl-associated X increased in the A549 cells treated with telmisartan. Additionally, levels of phosphorylated RAC serine/threonine-protein kinase (p-AKT), p-mechanistic target of rapamycin, p70-S6 kinase and cyclin D1 was decreased in the telmisartan-treated group. Therefore, the current study reveals that telmisartan-induced NSCLC apoptosis may be regulated via the phosphoinositide 3-kinase/AKT signaling pathway, which indicates that it may be a potential novel drug for clinical NSCLC treatment. IntroductionLung cancer, the most common type of cancer, has the highest morbidity rate among all types of malignancies worldwide (1,2), accounting for 30% of all incidences of cancer-associated mortality (3). In clinical practice, the two major types of lung cancer are small cell lung cancer (SCLC) and non-SCLC (NSCLC) (4), of which NSCLC accounts for ~80% of all lung cancer cases (5). Current therapies for NSCLC include chemotherapy, radiotherapy, targeted therapy and surgery, which are used alone or in combination (6). Despite the use of these therapies, the overall 5-year survival rate of NSCLC remains low, at 15% (7). Owing to the development of drug resistance and the severe side effects experienced by patients, effective and safe novel agents are required for the treatment of NSCLC (1).Angiotensin II (Ang II), a key biological peptide in the renin-angiotensin system, is a vasoconstrictor that controls cardiovascular function and renal homeostasis (8). Ang II receptor blockers (ARBs) are extensively used as anti-hypertensive drugs (9). Studies have reported that angiogenesis is essential for tumor progression and metastasis (10,11). Furthermore, studies have demonstrated that ARBs have the potential possibility to restrain the growth of several types of cancer cells (12,13). Ang II binds two receptor subtypes, the Ang II type 1 receptor (AT1R) and the Ang II type 2 receptor (AT2R), to mediate a series of biological effects (14). AT1R mediates the main functions of Ang II, including tumor growth and angiogenesis (15). Treatment with telmisartan, a spe...

show abstract

Angiotensin 1‐7 inhibits angiotensin II‐stimulated head and neck cancer progression

Cited by 26 publications

References 32 publications

Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2

Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2

Biological behavior of oral squamous cell carcinoma in the background of novel corona virus infection

Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway

Contact Info

Product

Resources

About